Mainz Biomed B.V. (MYNZ)
5.50
0.28 (5.36%)
At close: Feb 20, 2025, 3:59 PM
5.77
4.92%
After-hours: Feb 20, 2025, 05:29 PM EST
undefined% (undefined)
| Bid | 5.59 |
| Market Cap | 12.22M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -44.4 |
| PE Ratio (ttm) | -0.12 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 5.79 |
| Volume | 156,096 |
| Avg. Volume (20D) | 774,840 |
| Open | 5.09 |
| Previous Close | 5.22 |
| Day's Range | 5.09 - 5.84 |
| 52-Week Range | 0.18 - 8.20 |
| Beta | undefined |
About MYNZ
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and...
Industry Medical - Diagnostics & Research
Sector Healthcare
IPO Date Nov 5, 2021
Employees 65
Stock Exchange NASDAQ
Ticker Symbol MYNZ
Website https://mainzbiomed.com
Analyst Forecast
According to 3 analyst ratings, the average rating for MYNZ stock is "Hold." The 12-month stock price forecast is $14, which is an increase of 154.55% from the latest price.
Buy 33.33%
Hold 66.67%
Sell 0.00%
1 week ago
+11.28%
Mainz Biomed shares are trading higher after the c...
Unlock content with
Pro Subscription
2 months ago
+26.19%
Mainz Biomed shares are trading higher after the company announced it formed an agreement with Quest Diagnostics to support the commercialization of its next-gen screening test for colorectal cancer.
